Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 29

1.

The Italian Observational Study on Severe Osteoporosis (ISSO): 24-month results on incidence of fractures and adherence to treatment.

Idolazzi L, Maugeri D, Monti S, Massarotti M, Osella G, Barbagallo M, Del Fiacco R, Silvestri S; ISSO Study Group.

Clin Exp Rheumatol. 2016 Mar-Apr;34(2):247-53. Epub 2016 Feb 26.

PMID:
26940788
2.

Physical exercise and sarcopenia in older people: position paper of the Italian Society of Orthopaedics and Medicine (OrtoMed).

Iolascon G, Di Pietro G, Gimigliano F, Mauro GL, Moretti A, Giamattei MT, Ortolani S, Tarantino U, Brandi ML.

Clin Cases Miner Bone Metab. 2014 Sep;11(3):215-21.

3.

When the government actively faces the burden of osteoporosis: the Italian experience.

Brandi ML, Guglielmi G, Masala S, Minisola S, Ortolani S, Tarantino U, Simonetti G.

Arch Osteoporos. 2012;7:21-4. doi: 10.1007/s11657-012-0077-0. Epub 2012 Jul 26.

PMID:
23225277
4.

Official Positions for FRAX® clinical regarding international differences from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.

Cauley JA, El-Hajj Fuleihan G, Arabi A, Fujiwara S, Ragi-Eis S, Calderon A, Chionh SB, Chen Z, Curtis JR, Danielson ME, Hanley DA, Kroger H, Kung AW, Lesnyak O, Nieves J, Pluskiewicz W, El Rassi R, Silverman S, Schott AM, Rizzoli R, Luckey M; FRAX(®) Position Conference Members.

J Clin Densitom. 2011 Jul-Sep;14(3):240-62. doi: 10.1016/j.jocd.2011.05.015.

PMID:
21810532
5.

FRAX® International Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference.

Cauley JA, El-Hajj Fuleihan G, Luckey MM; FRAX(®) Position Development Conference Members.

J Clin Densitom. 2011 Jul-Sep;14(3):237-9. doi: 10.1016/j.jocd.2011.05.016.

PMID:
21810531
6.

Official Positions for FRAX® Bone Mineral Density and FRAX® simplification from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.

Lewiecki EM, Compston JE, Miller PD, Adachi JD, Adams JE, Leslie WD, Kanis JA, Moayyeri A, Adler RA, Hans DB, Kendler DL, Diez-Perez A, Krieg MA, Masri BK, Lorenc RR, Bauer DC, Blake GM, Josse RG, Clark P, Khan AA; FRAX® Position Development Conference Members.

J Clin Densitom. 2011 Jul-Sep;14(3):226-36. doi: 10.1016/j.jocd.2011.05.017.

PMID:
21810530
7.

FRAX(®) Bone Mineral Density Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference.

Lewiecki EM, Compston JE, Miller PD, Adachi JD, Adams JE, Leslie WD, Kanis JA; FRAX(®) Position Development Conference Members.

J Clin Densitom. 2011 Jul-Sep;14(3):223-5. doi: 10.1016/j.jocd.2011.05.018.

PMID:
21810529
8.

Official Positions for FRAX® clinical regarding biochemical markers from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.

McCloskey EV, Vasikaran S, Cooper C; FRAX(®) Position Development Conference Members.

J Clin Densitom. 2011 Jul-Sep;14(3):220-2. doi: 10.1016/j.jocd.2011.05.008.

PMID:
21810528
9.
10.
11.
12.

Official Positions for FRAX® clinical regarding smoking from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.

Dimai HP, Chandran M; FRAX(®)Position Development Conference Members.

J Clin Densitom. 2011 Jul-Sep;14(3):190-3. doi: 10.1016/j.jocd.2011.05.011.

PMID:
21810524
13.
14.

FRAX(®) Clinical Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference.

McCloskey EV, Binkley N; FRAX(®) Position Development Conference Members.

J Clin Densitom. 2011 Jul-Sep;14(3):181-3. doi: 10.1016/j.jocd.2011.05.013.

PMID:
21810522
15.

Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®). Executive Summary of the 2010 Position Development Conference on Interpretation and use of FRAX® in clinical practice.

Hans DB, Kanis JA, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Cooper C, Dawson-Hughes B, El-Hajj Fuleihan G, Leslie WD, Lewiecki EM, Luckey MM, McCloskey EV, Papapoulos SE, Poiana C, Rizzoli R; FRAX(®) Position Development Conference Members.

J Clin Densitom. 2011 Jul-Sep;14(3):171-80. doi: 10.1016/j.jocd.2011.05.007.

PMID:
21810521
16.

Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial.

Cauley JA, Black D, Boonen S, Cummings SR, Mesenbrink P, Palermo L, Man Z, Hadji P, Reid IR; HORIZON Pivotal Fracture Group.

J Bone Miner Res. 2011 May;26(5):984-92. doi: 10.1002/jbmr.292.

17.

Baseline observations from the POSSIBLE EU® study: characteristics of postmenopausal women receiving bone loss medications.

Freemantle N, Cooper C, Roux C, Díez-Pérez A, Guillemin F, Jonsson B, Ortolani S, Pfeilschifter J, Horne R, Kakad S, Shepherd S, Möller G, Marciniak A, Martinez L.

Arch Osteoporos. 2010 Dec;5(1-2):61-72. Epub 2010 Feb 27.

18.

Analysis of the costs and consequences of adherence to therapy in hip fracture patients. Results of a longitudinal analysis of.

Tarantino U, Ortolani S, Degli Esposti L, Veronesi C, Buda S, Brandi ML.

Clin Cases Miner Bone Metab. 2011 Jan;8(1):57-62.

19.

Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial.

Eastell R, Lang T, Boonen S, Cummings S, Delmas PD, Cauley JA, Horowitz Z, Kerzberg E, Bianchi G, Kendler D, Leung P, Man Z, Mesenbrink P, Eriksen EF, Black DM; HORIZON Pivotal Fracture Trial.

Osteoporos Int. 2010 Jul;21(7):1277-85. doi: 10.1007/s00198-009-1077-9. Epub 2009 Oct 3.

20.

Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.

Eastell R, Black DM, Boonen S, Adami S, Felsenberg D, Lippuner K, Cummings SR, Delmas PD, Palermo L, Mesenbrink P, Cauley JA; HORIZON Pivotal Fracture Trial.

J Clin Endocrinol Metab. 2009 Sep;94(9):3215-25. doi: 10.1210/jc.2008-2765. Epub 2009 Jun 30.

Supplemental Content

Loading ...
Support Center